Temozolomid in der Behandlung maligner Gliome

Zusammenfassung

Temozolomid (Handelsname Temodal®) ist ein orales, alkylierendes Chemotherapeutikum, das zur Behandlung von malignen Gliomen beim Rezidiv oder Progress seit 1999 europaweit zugelassen ist. In dieser Übersicht sollen Pharmakologie, Nebenwirkungen und Indikationen für den Einsatz von Temozolomid bei malignen Gliomen dargestellt werden. Ferner wird auf aktuelle Therapiestudien eingegangen, deren Ergebnisse einen Einfluss auf die zukünftigen Einsatzmöglichkeiten von Temozolomid in der Neuroonkologie haben könnten.

Abstract

Temozolomide is an orally administered, alkylating agent with approval for recurrent and progressive malignant gliomas. Here we review the pharmacological properties of temozolomide, its possible side effects and current indications for the treatment of malignant gliomas. Some current treatment trials on temozolomide are discussed, which may have an impact on its role in future Neuro-Oncology.

Literatur

• 1 DeAngelis L. Brain Tumors.  N Engl J Med. 2001;  344 114-123
• 2 Hill J R, Kuriyama N, Kuriyama H. et al . Molecular genetics of brain tumors.  Arch Neurol. 1999;  56 439-441
• 3 Hofer S, Herrmann R. Chemotherapy for malignant brain tumors of astrocytic and oligodendroglial lineage.  J Cancer Res Clin Oncol. 2001;  127 91-95
• 4 Cairncross G, Macdonald D, Ludwin S. et al . Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group.  J Clin Oncol. 1994;  12 2013-2021
• 5 van den Bent M J, Kros J M, Heimans J J. Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine.  , CCNU and vincristine chemotherapy et al. Dutch Neuro-oncology Group. Neurology. 1998;  51 1140-1145
• 6 Streffer J, Schabet M, Bamberg M. et al . A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors.  J Neurol. 2000;  247 297-302
• 7 The Medical Research Council Brain Tumor Working Party . Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytoma: a medical research council trial.  J Clin Oncol. 2001;  19 509-518
• 8 Chamberlain M C, Jaeckle K A. Medical Research Council adjuvant trial in high-grade gliomas.  J Clin Oncol. 2001;  19 3997-3999
• 9 DeAngelis L M, Burger P C, Green S B. et al . Malignant glioma: who benefits from adjuvant chemotherapy?.  Ann Neurol. 1998;  44 691-695
• 10 Weller M. Interdisziplinäre Leitlinien für die Diagnostik und Therapie supratentorieller Gliome des Erwachsenenalters.  Fassung vom 19.01.2002 (www.neuroonkologie.de)
• 11 Stewart L A. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials.  Lancet. 2002;  359 1011-1018
• 12 Wong E T, Hess K R, Gleason M J. et al . Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.  J Clin Oncol. 1999;  17 2572-2578
• 13 Raymond E, Izbicka E, Soda H. et al . Activity of temozolomide against human tumor colony-forming units.  Clin Cancer Res. 1997;  3 1769-1774
• 14 Patel M, McCully C, Godwin K. et al . Plasma and cerebrospinal fluid pharmacokinetics of temozolomide.  Proc Am Soc Clin Oncol. 1995;  14 461
• 15 Brock S B, Newlands E S, Steven R. et al . Phase I trial of temozolomide using an extended continuous oral schedule.  Cancer Res. 1998;  58 4363-4367
• 16 Yung W K, Prados M D, Yaya-Tur R. et al . Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group.  J Clin Oncol. 1999;  17 2762-2771
• 17 Yung W K, Albright R E, Olson J. et al . A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse.  Br J Cancer. 2000;  83 588-593
• 18 Brada M, Hoang-Xuan K, Rampling R. et al . Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.  Ann Oncol. 2001;  12 259-266
• 19 Osoba D, Brada M, Yung W K. et al . Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme.  J Clin Oncol. 2000;  18 1481-1491
• 20 Stupp R, Dietrich P Y, Ostermann K S. et al . Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.  J Clin Oncol. 2002;  20 1375-1382
• 21 Chinot O L, Honore S, Dufour H. et al . Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.  J Clin Oncol. 2001;  19 2449-2455
• 22 van den Bent M J, Keime-Guibert F, Brandes A A. et al . Temozolomide chemotherapy in recurrent oligodendroglioma.  Neurology. 2001;  57 340-342
• 23 Stupp R, Gander M, Leyvraz S. et al . Current and future developments in the use of temozolomide for the treatment of brain tumours.  Lancet Oncol. 2001;  2 552-560
• 24 Friedman H S, McLendon R E, Kerby T. et al . DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.  J Clin Oncol. 1998;  16 3851-3857
• 25 Hirose Y, Berger M S, Pieper R O. p53 effects both the duration of G₂/M arrest and the fate of temozolomide-treated human glioblastoma cells.  Cancer Res. 2001;  61 1957-1963
• 26 Brandes A A, Vastola F, Basso U. Temozolomide in glioblastoma multiforme of the elderly.  Tumori. 2002;  88 69-70
• 27 Koch D, Hopf N J, Hopf H C. et al . Behandlung maligner Gliome mit Temozolomid - Klinische Erfahrungen an 48 Patienten.  Akt Neurol. 2001;  28 (Suppl 2) 597
• 28 Newlands E S, O'Reilly S M, Glaser M G. et al . The Charing Cross Hospital experience with temozolomide in patients with gliomas.  Eur J Cancer. 1996;  32 2236-2241